Target
Caspase-6 SBDD
Halting the Inflammation Process
- Activated in human fibrotic conditions and NASH
- Inhibitors are efficacious in HFD mouse in vivo NASH model
- Robust BC and cell assays
- Inhibitors (IC50 = 1-10 nM) of active and inactive forms
SolubleLow CYP liabilityPermeableLow hERG liabilityMetabolically stableSelective - Protein crystal structures solved for both forms
- SBDD enabled
- Allosteric inhibition observed
- Implicated in neurodegeneration
![caspase6-img1](https://elgiatherapeutics.com/wp-content/uploads/2020/12/caspase6-img1.jpg)
Lorem Ipsum Dolore Sectum
![caspase6-img-veid](https://elgiatherapeutics.com/wp-content/uploads/2020/12/caspase6-img-veid.gif)
![caspase6-img-lamin](https://elgiatherapeutics.com/wp-content/uploads/2020/12/caspase6-img-lamin.gif)